Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Skin and subcutaneous tissue disorders – page 5

  • 843 clinical trials
  • 269 recruiting
  • 353 conditions
  • 25 countries

Conditions in this area

353 conditions with trials, the busiest first

Dermatitis atopic88Malignant melanoma79Systemic lupus erythematosus61Psoriasis53Hidradenitis47Psoriatic arthropathy45Systemic scleroderma39Metastatic malignant melanoma32Vitiligo23Hereditary angioedema22Chronic spontaneous urticaria19Malignant melanoma stage III17Dermatomyositis15Non-small cell lung cancer15Alopecia areata14Cutaneous lupus erythematosus14Rheumatoid arthritis14Diabetic foot13Basal cell carcinoma12Malignant melanoma stage IV12Actinic keratosis11Hepatocellular carcinoma11Neurodermatitis11Squamous cell carcinoma of skin11+329

Clinical trials in Skin and subcutaneous tissue disorders

843 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

843 clinical trials

Systemic scleroderma+4

Recruiting
InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Kyv-101
  • Sponsor:Kyverna Therapeutics Inc.

Herpes zoster

Recruiting
Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:65+ years · Healthy volunteers
  • Substances:Recombinant Varicella Zoster Virus Glycoprotein E
  • Sponsor:Gentofte Hospital

Systemic scleroderma+5

Recruiting
InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:Amsterdam UMC Stichting

Hidradenitis

Recruiting
Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:SAR445399
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Skin wound

Recruiting
Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Oxygen
  • Sponsor:Medical University Of Graz

Hereditary angioedema

Recruiting
InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Donidalorsen
  • Sponsor:Ionis Pharmaceuticals Inc.

Still's disease+1

Recruiting
InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years
  • Substances:Apremilast
  • Sponsor:Amgen Inc.

Systemic lupus erythematosus

Recruiting
Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Litifilimab
  • Sponsor:Biogen Idec Research Limited

Neuroendocrine carcinoma of the skin

Recruiting
Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH

Skin cancer

Recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bifikafusp Alfa
  • Sponsor:Philogen S.p.A.

Bladder cancer+4

Recruiting
Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Semmelweis University

Dermatitis atopic

Recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Dupilumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Substances studied in this area

The therapies tested most often in Skin and subcutaneous tissue disorders trials.

Pembrolizumab57 clinical trialsNivolumab33 clinical trialsSodium Chloride22 clinical trialsDeucravacitinib19 clinical trialsCemiplimab18 clinical trialsUpadacitinib17 clinical trialsIpilimumab15 clinical trialsRituximab13 clinical trialsCyclophosphamide12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.